Alcon/$ALC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Primary listing
NYSE
Employees
25,000
Headquarters
Geneva, Switzerland
Website
Alcon Metrics
BasicAdvanced
$34bn
41.45
$1.67
0.70
$0.23
0.34%
Price and volume
Market cap
$34bn
Beta
0.7
52-week high
$91.61
52-week low
$61.84
Average daily volume
2.1m
Dividend rate
$0.23
Financial strength
Current ratio
2.204
Quick ratio
1.221
Long term debt to equity
20.806
Total debt to equity
23.774
Dividend payout ratio (TTM)
20.27%
Interest coverage (TTM)
6.16%
Profitability
EBITDA (TTM)
2,313
Gross margin (TTM)
56.14%
Net profit margin (TTM)
7.70%
Operating margin (TTM)
11.99%
Effective tax rate (TTM)
16.94%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
2.54%
Return on equity (TTM)
3.71%
Valuation
Price to earnings (TTM)
41.451
Price to revenue (TTM)
3.192
Price to book
1.25
Price to tangible book (TTM)
6.9
Price to free cash flow (TTM)
21.338
Free cash flow yield (TTM)
4.69%
Free cash flow per share (TTM)
3.239
Dividend yield (TTM)
0.34%
Forward dividend yield
0.34%
Growth
Revenue change (TTM)
7.14%
Earnings per share change (TTM)
-25.90%
3-year revenue growth (CAGR)
6.19%
3-year earnings per share growth (CAGR)
34.16%
3-year dividend per share growth (CAGR)
15.85%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
MarketBeat·3 weeks ago
Mexican Gold Announces Subscription Receipt Financing and Loan to Alcon Silver in Connection with Arrangement
Newsfile Corp·1 month ago
Swiss eye care firm Alcon's quarterly revenue rises, driven by product launches
Reuters·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.